Effects of complete vagotomy and blockage of cell adhesion molecules on interferon-α induced behavioral changes in mice

Behavioural Brain Research

Volumn 240, Issue 1, 2013, Pages 1-10

  Friebe, Astrid ^a,b   Brünahl, Christian ^a,c   Karimi, Khalil ^a   Schäfer, Martin ^d   Juckel, Georg ^b   Sakic, Boris ^a   Arck, Petra ^a,c  

^a MCMASTER UNIVERSITY   (Canada)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d KLINIKEN ESSEN MITTE   (Germany)

Author keywords

Adhesion molecules; Interferon ; Mood changes; Vagus nerve

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR CHANGE; BEHAVIOR DISORDER; CELL COMMUNICATION; CONTROLLED STUDY; DEPRESSION; IMMUNE SYSTEM; LIGHT DARK CYCLE; MALE; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; VAGOTOMY;

ACTIVATED-LEUKOCYTE CELL ADHESION MOLECULE; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; CELL ADHESION MOLECULES; DEPRESSION; IMMUNOLOGIC FACTORS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-ALPHA; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MALE; MICE; MICE, INBRED BALB C; VAGOTOMY; VAGUS NERVE;

EID: 84870788538     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.11.011     Document Type: Article

References (56)

1. Kent S., Bluthé R.M., Kelley K.W., Dantzer R. Sickness behavior as a new target for drug development. Trends in Pharmacological Sciences 1992, 13(1):24-28.
2. Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Annals of the New York Academy of Sciences 2001, 933:222-234.
3. Dantzer R., Kelley K.W. Twenty years of research on cytokine-induced sickness behavior. Brain, Behavior, and Immunity 2007, 21(2):153-160.
4. Myers J.S. Proinflammatory cytokines and sickness behavior: implications for depression and cancer-related symptoms. Oncology Nursing Forum 2008, 35(5):802-807.
5. Yirmiya R., Weidenfeld J., Pollak Y., Morag M., Morag A., Avitsur R., et al. Cytokines, " depression due to a general medical condition" , and antidepressant drugs. Advances in Experimental Medicine and Biology 1999, 461:283-316.
6. Lorton D., Lubahn C.L., Zautra A.J., Bellinger D.L. Proinflammatory cytokines and sickness behavior in rheumatic diseases. Current Pharmaceutical Design 2008, 14(13):1242-1260.
7. Walker J.R., Ediger J.P., Graff L.A., Greenfeld J.M., Clara I., Lix L., et al. The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. American Journal of Gastroenterology 2008, 103(8):1989-1997.
8. Agarwala S.S., Kirkwood J.M. Update on the role of adjuvant interferon for high risk melanoma. Forum 2000, 10(3):230-239.
9. Zdilar D., Franco-Bronson K., Buchler N., Locala J.A., Younossi Z.M. Hepatitis C, interferon alfa, and depression. Hepatology 2000, 31(6):1207-1211.
10. Dieperink E., Willenbring M., Ho S.B. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. American Journal of Psychiatry 2000, 157(6):867-876.
11. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B., et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26(5):643-652.
12. Schaefer M., Engelbrecht M.A., Gut O., Fiebich B.L., Bauer J., Schmidt F., et al. Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2002, 26(4):731-746.
13. Friebe A., Schwarz M.J., Schmid-Wendtner M., Volkenandt M., Schmidt F., Horn M., et al. Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma. Journal of Immunotherapy 2007, 30(3):333-337.
14. Quan N., Banks W.A. Brain-immune communication pathways. Brain, Behavior, and Immunity 2007, 21(6):727-735.
15. Banks W.A. The blood-brain barrier in psychoneuroimmunology. Immunology and Allergy Clinics of North America 2009, 29(2):223-228.
16. Banks W.A., Erickson M.A. The blood-brain barrier and immune function and dysfunction. Neurobiology of Disease 2010, 37(1):26-32.
17. Watkins L.R., Maier S.F., Goehler L.E. Cytokine-to-brain communication: a review & analysis of alternative mechanisms. Life Sciences 1995, 57(11):1011-1026.
18. Bluthé R.M., Walter V., Parnet P., Layé S., Lestage J., Verrier D., et al. Lipopolysaccharide induces sickness behaviour in rats by a vagal mediated mechanism. Comptes Rendus de l Academie des Sciences. Serie III, Sciences de la Vie 1994, 317(6):499-503.
19. Luheshi G.N., Bluthé R.M., Rushforth D., Mulcahy N., Konsman J.P., Goldbach M., et al. Vagotomy attenuates the behavioural but not the pyrogenic effects of interleukin-1 in rats. Autonomic Neuroscience 2000, 85(1-3):127-132.
20. Schaefer M., Horn M., Schmidt F., Schmid-Wendtner M.H., Volkenandt M., Ackenheil M., et al. Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha. Brain, Behavior, and Immunity 2004, 18(6):555-562.
21. Cayrol R., Wosik K., Berard J.L., Dodelet-Devillers A., Ifergan I., Kebir H., et al. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nature Immunology 2008, 9(2):137-145.
22. Van der Kleij H., O'Mahony C., Shanahan F., O'Mahony L., Bienenstock J. Protective effects of Lactobacillus reuteri and Bifidobacterium infantis in murine models for colitis do not involve the vagus nerve. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 2008, 295(4):R1131-R1137.
23. Campfield L.A., Smith F.J., LeMagnen J. Altered endocrine pancreatic function following vagotomy: possible behavioral and metabolic bases for assessing completeness of vagotomy. Journal of the Autonomic Nervous System 1983, 9(1):283-300.
24. Blois S., Tometten M., Kandil J., Hagen E., Klapp B.F., Margni R.A., et al. Intercellular adhesion molecule-1/LFA-1 cross talk is a proximate mediator capable of disrupting immune integration and tolerance mechanism at the feto-maternal interface in murine pregnancies. Journal of Immunology 2005, 174(4):1820-1829.
25. Frenois F., Moreau M., O'Connor J., Lawson M., Micon C., Lestage J., et al. Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology 2007, 32(5):516-531.
26. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends in Immunology 2006, 27(1):24-31.
27. Borovikova L.V., Ivanova S., Zhang M., Yang H., Botchkina G.I., Watkins L.R., et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000, 405:458-462.
28. McCandless E.E., Klein R.S. Molecular targets for disrupting leukocyte trafficking during multiple sclerosis. Expert Reviews in Molecular Medicine 2007, 9(20):1-19.
29. Huston J.M., Rosas-Ballina M., Xue X., Dowling O., Ochani K., Ochani M., et al. Cholinergic neural signals to the spleen down-regulate leukocyte trafficking via CD11b. Journal of Immunology 2009, 183(1):552-559.
30. Hogan B.V., Peter M.B., Shenoy H.G., Horgan K., Hughes T.A. Surgery induced immunosuppression. Surgeon 2011, 9(1):38-43.
31. Kolseth I.B., Førland D.T., Risøe P.K., Flood-Kjeldsen S., Agren J., Reseland J.E., et al. Human monocyte responses to lipopolysaccharide and 9-cis retinoic acid after laparoscopic surgery for colon cancer. Scandinavian Journal of Clinical & Laboratory Investigation 2012, 72:593-601.
32. Avraham R., Benish M., Inbar S., Bartal I., Rosenne E., Ben-Eliyahu S. Synergism between immunostimulation and prevention of surgery-induced immune suppression: an approach to reduce post-operative tumor progression. Brain, Behavior, and Immunity 2010, 24(6):952-958.
33. Toft P., Dagnaes-Hansen Tonnesen E., Petersen M.S. Influence of surgery and endotoxin-induced sepsis combined on natural killer cell activity, oxidative burst of granulocytes and antigen presentation capability of monocytes. Acta Anaesthesiologica Scandinavica 2002, 46:405-410.
34. Makino M., Kitano Y., Hirohashi M., Takasuna K. Enhancement of immobility in mouse forced swimming test by treatment with human interferon. European Journal of Pharmacology 1998, 356(1):1-7.
35. Makino M., Kitano Y., Komiyama C., Takasuna K. Human interferon-alpha increases immobility in the forced swimming test in rats. Psychopharmacology 2000, 148(1):106-110.
36. Makino M., Kitano Y., Komiyama C., Hirohashi M., Kohno M., Moriyama M., et al. Human interferon-alpha induces immobility in the mouse forced swimming test: involvement of the opioid system. Brain Research 2000, 852(2):482-484.
37. Sammut S., Goodall G., Muscat R. Acute interferon-alpha administration modulates sucrose consumption in the rat. Psychoneuroendocrinology 2000, 26(3):261-272.
38. Fahey B., Hickey B., Kelleher D., O'Dwyer A.M., O'Mara S.M. The widely-used anti-viral drug interferon-alpha induces depressive- and anxiogenic-like effects in healthy rats. Behavioural Brain Research 2007, 182(1):80-87.
39. De La Garza R., Asnis G.M., Pedrosa E., Stearns C., Migdal A.L., Reinus J.F., et al. Recombinant human interferon-alpha does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2005, 29(5):781-792.
40. Loftis J.M., Wall J.M., Pagel R.L., Hauser P. Administration of pegylated interferon-alpha-2a or -2b does not induce sickness behavior in Lewis rats. Psychoneuroendocrinology 2006, 31(10):1289-1294.
41. Loftis J.M., Hauser P., Macey T.A., Lowe J.D. Can rodents be used to model interferon-alpha-induced depressive symptoms?. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2006, 30(7):1364-1365.
42. Wang J., Dunn A.J., Roberts A.J., Zhang H. Decreased immobility in swimming test by homologous interferon-alpha in mice accompanied with increased cerebral tryptophan level and serotonin turnover. Neuroscience Letters 2009, 452(2):96-100.
43. Lang J.Y., Wang J.S., Zhai H.F., Fang Q., Wu P., Lu L. Interferon-alpha reinstates morphine-conditioned place preference through opioid receptors in rats. Behavioural Pharmacology 2009, 20(2):166-173.
44. Friebe A., Horn M., Schmidt F., Janssen G., Schmid-Wendtner M.H., Volkenandt M., et al. Dose dependent development of depressive symptoms during adjuvant interferon-alpha treatment of patients with malignant melanoma. Psychosomatics 2010, 51:466-473.
45. Yamada T., Yamanaka I. Microglial localization of a-interferon receptor in human brain tissues. Neuroscience Letters 1995, 189:73-76.
46. Delhaye S., Paul S., Blakqori G., Minet M., Weber F., Staeheli P., et al. Neurons produce type I interferon during viral encephalitis. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:7835-7840.
47. Okada K., Kuroda E., Yoshida Y., Yamashita U., Suzumura A., Tsuji S. Effects of interferon-beta on the cytokine production of astrocytes. Journal of Neuroimmunology 2005, 159:48-54.
48. Dafny N. Is interferon-α a neuromodulator?. Brain Research Reviews 1998, 26:1-15.
49. Taylor J.L., Grossberg S.E. The effects of interferon-alpha on the production and action of other cytokines. Seminars in Oncology 1998, 25(1 Suppl. 1):23-29.
50. Bonaccorso S., Puzella A., Marino V., Pasquini M., Biondi M., Artini M., et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Research 2001, 105(1-2):45-55.
51. Blatteis C.M. The afferent signalling of fever. Journal of Physiology 2000, 526(Pt 3):470.
52. Banks W.A., Kastin A.J., Broadwell R.D. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 1995, 2(4):241-248.
53. Pan W., Banks W.A., Kastin A.J. Permeability of the blood-brain and blood-spinal cord barriers to interferons. Journal of Neuroimmunology 1997, 76(1-2):105-111.
54. Shibata M., Blatteis C.M. Human recombinant tumor necrosis factor and interferon affect the activity of neurons in the organum vasculosum laminae terminalis. Brain Research 1991, 562:323-326.
55. Ek M., Kurosawa M., Lundeberg T., Ericsson A. Activation of vagal afferents after intravenous injection of interleukin-1b: role of endogenous prostaglandins. Journal of Neuroscience 1998, 18:9471-9479.
56. Olofsson P.S., Rosas-Ballina M., Levine Y.A., Tracey K.J. Rethinking inflammation: neural circuits in the regulation of immunity. Immunological Reviews 2012, 248:188-204.